Reported about 2 months ago
Hims & Hers Health, a telemedicine company, has seen its stock rise 74% this year, primarily due to its entry into the weight loss medication market with compounded versions of popular drugs like Ozempic. However, concerns about the safety and efficacy of compounded medications, coupled with the potential for public relations issues and legal liabilities, suggest that the stock may face significant challenges ahead. Analysts recommend more established companies in the weight loss industry as safer investment options.
Source: YAHOO